Emily Gibson McDonald

Emily Gibson McDonald

Auto-generated profile, based on publicly available information

Emily Gibson McDonald

Division of Experimental Medicine, Department of Medicine, McGill University , Montreal, Quebec

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2020 in Annals of Internal Medicine
Verified
Journal Article
Open access
CSCaleb Skipper
Caleb Skipper
KPKatelyn A. Pastick
Katelyn A. Pastick
NENicole W. Engen
Nicole W. Engen
ABAnanta S. Bangdiwala
Ananta S. Bangdiwala
MAMahsa Abassi
Mahsa Abassi
DBDavid Boulware
David Boulware
There is no known effective oral therapy for early COVID-19. This randomized trial evaluated effects of oral hydroxychloroquine on symptoms and disease severity in adult outpatients with early COVI... Visual Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 There is no known effective oral therapy for early COVID-19. This randomized, double-blind, placebo-controlled trial... Background: No effective oral therapy exists for early coronavirus disease 2019 (COVID-19). Objective: To investigate whether hydroxychloroquine could reduce COVID-19 severity in adult outpatients....

18 January 2022 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
EMEmily G. McDonald
Emily G. McDonald
PWPeter E. Wu
Peter E. Wu
BRBabak Rashidi
Babak Rashidi
MWMarnie Goodwin Wilson
Marnie Goodwin Wilson
ÉBÉmilie Bortolussi-Courval
Émilie Bortolussi-Courval
TLTodd C. Lee
Todd C. Lee
Deprescribing is the medically supervised tapering or cessation of medications that are no longer needed or beneficial, including medications that are potentially inappropriate (PIMs), time delimited, ineffective, or that do not align with goals of care.1 After an acute care hospitalization, adverse drug events (ADEs) are common and up to 60% are considered preventable.2 Deprescribing PIMs at hospital discharge to prevent ADEs could be advantageous; however, several barriers exist.3,4 First, hospital practitioners focused on acute care requirements may be reluctant to alter long-term outpatient therapies managed by other prescribers, particularly if they do not follow patients postdischarge.5 Second, not all centers include routine pharmacist or geriatrician subspecialties to support interprofessional care. Third, some prescribers fear that stopping or reducing a drug can lead to adverse effects.6 Fourth, despite deprescribing opportunities, therapeutic inertia is common7,8; true even for low-risk drugs with no withdrawal concerns9 and more so for drugs with higher risks of harm.10 Even when adverse events occur, opportunities to deprescribe are not always recognized or acted on.11,12 To our knowledge, prior studies of interventions to reduce PIMs while in hospital13-15 have tended to be underpowered and nonrandomized or did not capture postdischarge ADEs.

3 July 2023 in JAMA Network Open
Verified
Journal Article
Closed access
PDF file
EMEmily G. McDonald
Emily G. McDonald
GAGloria Aggrey
Gloria Aggrey
AAAbdullah Tarık Aslan
Abdullah Tarık Aslan
MCMichael Casias
Michael Casias
NCNicolas Cortes-Penfield
Nicolas Cortes-Penfield
TLTodd C. Lee
Todd C. Lee
Infective endocarditis (IE) is an ancient illness that can be difficult to diagnose and treat, leading to substantial morbidity and mortality even in the modern era. The literature regarding the management of IE spans decades but features few high-quality randomized clinical trials. This second WikiGuidelines consensus statement addresses the evidence-based management of IE. The guideline was drafted by an independent, international consortium of medical professionals who previously established a collaborative method to construct pragmatic, real-world, clinical practice guidelines.1,2 WikiGuidelines provide clear recommendations when reproducible, high-quality data and/or hypothesis-confirming evidence is available and otherwise provide comprehensive clinical reviews summarizing different clinical approaches. WikiGuidelines offer clinician insights and are not intended to establish care mandates or medicolegal standards of care, nor to replace individual clinician judgment.

4 November 2024 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
ZNZachary Nelson
Zachary Nelson
AAAbdullah Tarik Aslan
Abdullah Tarik Aslan
NBNathan P Beahm
Nathan P Beahm
MBMichelle D Blyth
Michelle D Blyth
MCMatthew Cappiello
Matthew Cappiello
ALAlfredo J. Mena Lora
Alfredo J. Mena Lora
Importance: Traditional approaches to practice guidelines frequently result in dissociation between strength of recommendation and quality of evidence. Objective: To create a clinical guideline for the diagnosis and management of urinary tract infections that addresses the gap between the evidence and recommendation strength. Evidence Review: This consensus statement and systematic review applied an approach previously established by the WikiGuidelines Group to construct collaborative clinical guidelines. In May 2023, new and existing members were solicited for questions on urinary tract infection prevention, diagnosis, and management. For each topic, literature searches were conducted up until early 2024 in any language. Evidence was reported according to the WikiGuidelines charter: clear recommendations were established only when reproducible, prospective, controlled studies provided hypothesis-confirming evidence. In the absence of such data, clinical reviews were developed discussing the available literature and associated risks and benefits of various approaches. Findings: A total of 54 members representing 12 countries reviewed 914 articles and submitted information relevant to 5 sections: prophylaxis and prevention (7 questions), diagnosis and diagnostic stewardship (7 questions), empirical treatment (3 questions), definitive treatment and antimicrobial stewardship (10 questions), and special populations and genitourinary syndromes (10 questions). Of 37 unique questions, a clear recommendation could be provided for 6 questions. In 3 of the remaining questions, a clear recommendation could only be provided for certain aspects of the question. Clinical reviews were generated for the remaining questions and aspects of questions not meeting criteria for a clear recommendation. Conclusions and Relevance: In this consensus statement that applied the WikiGuidelines method for clinical guideline development, the majority of topics relating to prevention, diagnosis, and treatment of urinary tract infections lack high-quality prospective data and clear recommendations could not be made. Randomized clinical trials are underway to address some of these gaps; however further research is of utmost importance to inform true evidence-based, rather than eminence-based practice.

27 June 2019 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
PDF file
EMEmily G. McDonald
Emily G. McDonald
PWPeter E. Wu
Peter E. Wu
BRBabak Rashidi
Babak Rashidi
AFAlan J. Forster
Alan J. Forster
AHAllen Huang
Allen Huang
TLTodd C. Lee
Todd C. Lee

29 December 2022 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
KDKusha Davar
Kusha Davar
DCDevin Clark
Devin Clark
RCRobert M Centor
Robert M Centor
FDFernando Dominguez
Fernando Dominguez
BGBassam Ghanem
Bassam Ghanem
BSBrad Spellberg
Brad Spellberg
Like all fields of medicine, Infectious Diseases is rife with dogma that underpins much clinical practice. In this study, we discuss 2 specific examples of historical practice that have been overturned recently by numerous prospective studies: traditional durations of antimicrobial therapy and the necessity of intravenous (IV)-only therapy for specific infectious syndromes. These dogmas are based on uncontrolled case series from >50 years ago, amplified by the opinions of eminent experts. In contrast, more than 120 modern, randomized controlled trials have established that shorter durations of therapy are equally effective for many infections. Furthermore, 21 concordant randomized controlled trials have demonstrated that oral antibiotic therapy is at least as effective as IV-only therapy for osteomyelitis, bacteremia, and endocarditis. Nevertheless, practitioners in many clinical settings remain refractory to adopting these changes. It is time for Infectious Diseases to move beyond its history of eminent opinion-based medicine and truly into the era of evidenced-based medicine.